JP6761929B2 - Ｆｇｆ１９の新規な治療用途 - Google Patents

Ｆｇｆ１９の新規な治療用途 Download PDF

Info

Publication number
JP6761929B2
JP6761929B2 JP2018518786A JP2018518786A JP6761929B2 JP 6761929 B2 JP6761929 B2 JP 6761929B2 JP 2018518786 A JP2018518786 A JP 2018518786A JP 2018518786 A JP2018518786 A JP 2018518786A JP 6761929 B2 JP6761929 B2 JP 6761929B2
Authority
JP
Japan
Prior art keywords
muscle
fgf19
mice
mass
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018518786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519366A (ja
JP2018519366A5 (Direct
Inventor
フゥイルー−モニエ，エマニュエル
ヴィダル，ユベール
ルッジン，ジェローム
Original Assignee
ユニヴェルシテ クラウド ベルナール リヨン １
ユニヴェルシテ クラウド ベルナール リヨン １
アンスティテュート ナショナル ド ルシェルシュ プール ラグリキュルテュール，ラリマンタシォン エ ランヴィロンヌマン
アンスティテュート ナショナル ド ルシェルシュ プール ラグリキュルテュール，ラリマンタシォン エ ランヴィロンヌマン
アンセルム（アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル）
アンセルム（アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル）
ベルゲン テクノロジオベルフォリング エーエス
ベルゲン テクノロジオベルフォリング エーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴェルシテ クラウド ベルナール リヨン １, ユニヴェルシテ クラウド ベルナール リヨン １, アンスティテュート ナショナル ド ルシェルシュ プール ラグリキュルテュール，ラリマンタシォン エ ランヴィロンヌマン, アンスティテュート ナショナル ド ルシェルシュ プール ラグリキュルテュール，ラリマンタシォン エ ランヴィロンヌマン, アンセルム（アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル）, アンセルム（アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル）, ベルゲン テクノロジオベルフォリング エーエス, ベルゲン テクノロジオベルフォリング エーエス filed Critical ユニヴェルシテ クラウド ベルナール リヨン １
Publication of JP2018519366A publication Critical patent/JP2018519366A/ja
Publication of JP2018519366A5 publication Critical patent/JP2018519366A5/ja
Application granted granted Critical
Publication of JP6761929B2 publication Critical patent/JP6761929B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018518786A 2015-06-25 2016-06-24 Ｆｇｆ１９の新規な治療用途 Active JP6761929B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305990.2 2015-06-25
EP15305990.2A EP3108893A1 (en) 2015-06-25 2015-06-25 Novel therapeutic use of fgf19
PCT/EP2016/064671 WO2016207354A1 (en) 2015-06-25 2016-06-24 Novel therapeutic use of fgf19

Publications (3)

Publication Number Publication Date
JP2018519366A JP2018519366A (ja) 2018-07-19
JP2018519366A5 JP2018519366A5 (Direct) 2019-08-22
JP6761929B2 true JP6761929B2 (ja) 2020-09-30

Family

ID=53498933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018518786A Active JP6761929B2 (ja) 2015-06-25 2016-06-24 Ｆｇｆ１９の新規な治療用途

Country Status (5)

Country Link
US (1) US10695403B2 (Direct)
EP (2) EP3108893A1 (Direct)
JP (1) JP6761929B2 (Direct)
CA (1) CA2997652A1 (Direct)
WO (1) WO2016207354A1 (Direct)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2726511T3 (da) 2011-07-01 2019-09-23 Ngm Biopharmaceuticals Inc Sammensætninger, anvendelser og fremgangsmåder til behandling af stofskiftesygdomme og -lidelser
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
CA2892152A1 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
CA2895517C (en) 2012-12-27 2022-10-11 Ngm Biopharmaceuticals, Inc. Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
CA3082794A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals Inc. Methods for treatment of bile acid-related disorders
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
AU2017353982B2 (en) * 2016-11-04 2021-05-06 Children's Hospital Medical Center Liver organoid compositions and methods of making and using same
JP2020100591A (ja) * 2018-12-21 2020-07-02 味の素株式会社 筋質向上剤
CN112057606B (zh) * 2020-09-14 2023-09-19 上海市儿童医院 Fgf19在治疗和/或预防脓毒症诱发的器官损伤的药物中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69839571D1 (de) * 1997-11-25 2008-07-10 Genentech Inc Fibroblasten-wachstumsfaktor-19
US20040126852A1 (en) * 1997-11-25 2004-07-01 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
AU2007221245A1 (en) * 2006-02-28 2007-09-07 The Trustees Of Boston University Metabolic regulators and uses thereof
CN102656266B (zh) * 2009-10-15 2016-08-03 霍夫曼-拉罗奇有限公司 具有改变的受体特异性的嵌合成纤维细胞生长因子
DK2726511T3 (da) * 2011-07-01 2019-09-23 Ngm Biopharmaceuticals Inc Sammensætninger, anvendelser og fremgangsmåder til behandling af stofskiftesygdomme og -lidelser

Also Published As

Publication number Publication date
EP3313430A1 (en) 2018-05-02
EP3108893A1 (en) 2016-12-28
JP2018519366A (ja) 2018-07-19
US20180369331A1 (en) 2018-12-27
WO2016207354A1 (en) 2016-12-29
EP3313430B1 (en) 2020-11-18
CA2997652A1 (en) 2016-12-29
US10695403B2 (en) 2020-06-30

Similar Documents

Publication Publication Date Title
JP6761929B2 (ja) Ｆｇｆ１９の新規な治療用途
De Blasio et al. Placental restriction of fetal growth reduces size at birth and alters postnatal growth, feeding activity, and adiposity in the young lamb
Ajuwon et al. Adiponectin inhibits LPS-induced NF-κB activation and IL-6 production and increases PPARγ2 expression in adipocytes
Arngrim et al. Migraine induced by hypoxia: an MRI spectroscopy and angiography study
Haddad et al. IL-6-induced skeletal muscle atrophy
Sobiś et al. Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity
Prandota Possible pathomechanisms of sudden infant death syndrome: key role of chronic hypoxia, infection/inflammation states, cytokine irregularities, and metabolic trauma in genetically predisposed infants
Vanderheyden et al. Greater lactate accumulation following an acute bout of high-intensity exercise in males suppresses acylated ghrelin and appetite postexercise
EP3043789B1 (en) Use of a ppar-delta agonists for treating muscle atrophy
Sanderson The epidemic of canine obesity and its role in osteoarthritis
Boesen et al. Effect of growth hormone on aging connective tissue in muscle and tendon: gene expression, morphology, and function following immobilization and rehabilitation
Murakami et al. Congenital generalized lipodystrophy type 4 with muscular dystrophy: clinical and pathological manifestations in early childhood
Harris et al. Inflammatory bowel disease causes reversible suppression of osteoblast and chondrocyte function in mice
Cottrell et al. Glucagon-like peptide-2 protects against TPN-induced intestinal hexose malabsorption in enterally refed piglets
Mendez-Gutierrez et al. Endocrine mechanisms connecting exercise to brown adipose tissue metabolism: a human perspective
CN107375910B (zh) PTHrP在制备治疗男性性腺功能低下综合征中的应用
Yoshimura et al. Ghrelin activation by ingestion of medium-chain triglycerides in healthy adults: a pilot trial
Miller et al. Dietary stimulation of the endogenous somatotropic axis in weaner and grower-finisher pigs using medium chain triglycerides and cysteamine hydrochloride
Oświęcimska et al. Chemerin serum levels in girls with anorexia nervosa
Wang et al. Time-restricted feeding mitigates HFD-induced sarcopenic obesity in aging mice through improving the sensitivity of FGF21
Shelke et al. Impact of yoga practice on lipid profile and insulin resistance in overweight and obese individuals–A Pilot Study
KR102523844B1 (ko) Lgi3 유래 펩타이드를 유효성분으로 포함하는 고지혈증 및 지방간의 예방, 치료, 또는 개선용 조성물
Uehara et al. Churg-Strauss syndrome presenting as myositis following unaccustomed exercise
JP2007505892A (ja) 向上した成長障害の処置方法
He et al. One case of pituitary stalk interruption syndrome associated with liver cirrhosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200630

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200728

R150 Certificate of patent or registration of utility model

Ref document number: 6761929

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250